대한핵의학회지 (1967년~2009년)
Nucl Med Mol Imaging 2006;40(5)237~242
종양 표적 유전자 치료
(Tumor targeted gene therapy)
Author 강주현,
Joo Hyun Kang, Ph.D.
Affiliation 원자력의학원 핵의학연구실
Laboratory of Nuclear Medicine, Korea Institute of Radiological and Medical Science, Seoul, Korea
Abstract

Knowledge of molecular mechanisms governing malignant transformation brings new opportunities for therapeutic intervention against cancer using novel approaches. One of them is gene therapy based on the transfer of genetic material to an organism with the aim of correcting a disease. The application of gene therapy to the cancer treatment has led to the development of new experimental approaches such as suicidal gene therapy, inhibition of oncogenes and restoration of tumor-suppressor genes. Suicidal gene therapy is based on the expression in tumor cells of a gene encoding an enzyme that converts a prodrug into a toxic product. Representative suicidal genes are Herpes simplex virus type 1 thymidine kinase (HSV1-tk) and cytosine deaminase (CD). Especially, physicians and scientists of nuclear medicine field take an interest in suicidal gene therapy because they can monitor the location and magnitude, and duration of expression of HSV1-tk and CD by PET scanner.(Nucl Med Mol Imaging 2006;40(5):237-242)

Keyword gene therapy, PET imaging, prodrug therapy, suicidal gene therapy, tumor targeting
Full text Article 4005237.pdf 4005237.pdf
(03121)서울시 종로구 지봉로 29 금호팔레스빌딩 1705호
TEL : 02-745-2040 FAX : 02-745-3833 E-mail : ksnm@ksnm.or.kr
Copyright 2012 by The Korean Society of Nuclear Medicine(KSNM)